Ishita drugs & indus and Industries Limited has submitted a regulatory disclosure under SEBI's substantial acquisition and takeover regulations. The filing, digitally signed by key personnel, outlines details of a corporate transaction involving share acquisition.

Transaction Details

The disclosure filed under Regulation 29(2) of SEBI (Substantial Acquisition and Takeovers) Regulations, 2011, identifies the following key parties and parameters:

Share Holdings Information

The regulatory filing includes details about share holdings before the acquisition under consideration. The document mentions 30,550 shares in the context of the transaction structure.

Regulatory Compliance

The disclosure document bears digital signatures from Abha Jagdishprasad Agrawal and Sumit Jagdishprasad Agrawal, dated February 14, 2026. The filing demonstrates the company's adherence to SEBI's transparency requirements for substantial acquisitions and takeovers.

Company Operations

Ishita Pharmaceuticals, identified as the acquirer, operates with contact details including phone number 91-79-26468353/886 and email ishitapharmal980@gmail.com . The company maintains a factory facility at 65/1, GIDC Industrial Estate, Wadhwan-363035, Surendranagar, India.

This regulatory disclosure ensures compliance with SEBI's substantial acquisition regulations and provides transparency to stakeholders regarding the corporate transaction involving the listed entity.

Ishita Drugs & Industries Limited announced its unaudited financial results for the third quarter of fiscal year 2026, ending December 31, 2025, following a board meeting held on February 7, 2026. The pharmaceutical company's performance showed a mixed trend with quarterly revenue declining year-over-year while nine-month figures demonstrated growth.

Quarterly Financial Performance

The company's Q3FY26 results reflected challenging market conditions with revenue from operations declining significantly compared to the previous year.

Other income for the quarter increased to ₹9.66 lakhs from ₹6.70 lakhs in Q3FY25. Total expenses decreased to ₹304.06 lakhs compared to ₹388.09 lakhs in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

Despite the quarterly decline, the company's nine-month performance showed positive momentum across key financial parameters.

The nine-month results indicate the company's resilience and ability to maintain growth trajectory despite quarterly fluctuations in the pharmaceutical sector.

Manufacturing Facility Upgradation Progress

The company made substantial progress on its manufacturing facility upgradation project for compliance with Revised Schedule M requirements during Q3FY26.

Key developments included the near completion of a new block designed to accommodate expanded warehouse area, along with repairs and renovations of various existing building sections. The company also placed orders for utilities and equipment necessary for Revised Schedule M compliance.

Board Meeting and Regulatory Compliance

The Board of Directors approved the unaudited financial results at their meeting held on February 7, 2026, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The results were reviewed by the Audit Committee and subjected to limited review by the company's statutory auditors, Jaymin Shah & Associates, Chartered Accountants.

Operational Highlights

The company operates within a single business segment focused on pharmaceutical business, as per Indian Accounting Standard (IndAS) on Operating Segments. The paid-up equity share capital remained stable at ₹299.03 lakhs with a face value of ₹10.00 per share. Employee benefit expenses for Q3FY26 stood at ₹36.08 lakhs compared to ₹35.73 lakhs in Q3FY25, while finance costs decreased to ₹1.54 lakhs from ₹1.83 lakhs year-over-year, indicating improved financial management.